485 related articles for article (PubMed ID: 28746799)
1. Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy.
Ohno Y; Toyoshima Y; Yurino H; Monma N; Xiang H; Sumida K; Kaneumi S; Terada S; Hashimoto S; Ikeo K; Homma S; Kawamura H; Takahashi N; Taketomi A; Kitamura H
Cancer Sci; 2017 Oct; 108(10):1959-1966. PubMed ID: 28746799
[TBL] [Abstract][Full Text] [Related]
2. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
3. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
4. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
5. Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation.
Kaplanov I; Carmi Y; Kornetsky R; Shemesh A; Shurin GV; Shurin MR; Dinarello CA; Voronov E; Apte RN
Proc Natl Acad Sci U S A; 2019 Jan; 116(4):1361-1369. PubMed ID: 30545915
[TBL] [Abstract][Full Text] [Related]
6. IFN-γ-STAT1-mediated NK2R expression is involved in the induction of antitumor effector CD8
Shen W; Wang X; Xiang H; Shichi S; Nakamoto H; Kimura S; Sugiyama K; Taketomi A; Kitamura H
Cancer Sci; 2023 May; 114(5):1816-1829. PubMed ID: 36715504
[TBL] [Abstract][Full Text] [Related]
7. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
8. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
[No Abstract] [Full Text] [Related]
10. Repeated cycles of 5-fluorouracil chemotherapy impaired anti-tumor functions of cytotoxic T cells in a CT26 tumor-bearing mouse model.
Wu Y; Deng Z; Wang H; Ma W; Zhou C; Zhang S
BMC Immunol; 2016 Sep; 17(1):29. PubMed ID: 27645787
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.
Marshall NA; Galvin KC; Corcoran AM; Boon L; Higgs R; Mills KH
Cancer Res; 2012 Feb; 72(3):581-91. PubMed ID: 22158905
[TBL] [Abstract][Full Text] [Related]
12. Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses.
Furumoto K; Arii S; Yamasaki S; Mizumoto M; Mori A; Inoue N; Isobe N; Imamura M
Int J Cancer; 2000 Sep; 87(5):665-72. PubMed ID: 10925360
[TBL] [Abstract][Full Text] [Related]
13. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
Desbois M; Le Vu P; Coutzac C; Marcheteau E; Béal C; Terme M; Gey A; Morisseau S; Teppaz G; Boselli L; Jacques Y; Béchard D; Tartour E; Cassard L; Chaput N
J Immunol; 2016 Jul; 197(1):168-78. PubMed ID: 27217584
[TBL] [Abstract][Full Text] [Related]
14. Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity.
Onda M; Kobayashi K; Pastan I
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4575-4582. PubMed ID: 30760587
[TBL] [Abstract][Full Text] [Related]
15. Combination Immunotherapy With LIGHT and Interleukin-2 Increases CD8 Central Memory T-Cells In Vivo.
Fernandez MF; Qiao G; Tulla K; Prabhakar BS; Maker AV
J Surg Res; 2021 Jul; 263():44-52. PubMed ID: 33631377
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy.
Kitamura H; Ohno Y; Toyoshima Y; Ohtake J; Homma S; Kawamura H; Takahashi N; Taketomi A
Cancer Sci; 2017 Oct; 108(10):1947-1952. PubMed ID: 28749573
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
[TBL] [Abstract][Full Text] [Related]
18. Potent antitumor activity of interleukin-27.
Hisada M; Kamiya S; Fujita K; Belladonna ML; Aoki T; Koyanagi Y; Mizuguchi J; Yoshimoto T
Cancer Res; 2004 Feb; 64(3):1152-6. PubMed ID: 14871851
[TBL] [Abstract][Full Text] [Related]
19. [The anti-tumor efforts of thymosin alpha1 on tumor lysate-pulsed dendritic cells in colon cancer in vitro and in vivo].
Ma YL; Zheng Z; Li BD; Xie SJ; Li GX; Yan QH; Cai JH
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Nov; 23(11):1046-9. PubMed ID: 17988589
[TBL] [Abstract][Full Text] [Related]
20. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
